BrightSpring Health Services, Inc. Tangible Equity Unit · BTSGU · FY2026 Q2 · Calendar Q3 2026
BrightSpring sustains strong growth as leverage falls and guidance holds
BrightSpring’s current results support the case for durable growth: revenue and adjusted EBITDA accelerated, demand remained strong across pharmacy and provider services, and management maintained its FY2026 outlook. The counterpoints are pharmacy-margin pressure, IRA exposure, generic competition, and execution risk as the company integrates acquisitions and expands infusion.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about BTSGU FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, current results show continued growth with lower reported leverage at 2.15x, rating upgrades and refinancing progress, while management added two ultra-narrow-network LDDs and reported 12 launches through Q2. The company also sharpened its stated IRA impact to approximately $200 million for Home and Community Pharmacy and $175 million for Specialty for the full year.
Guidance delta
Maintained. FY2026 outlook calls for 17–19.5% revenue growth and adjusted EBITDA of $820–$845 million.
Key takeaways
- Revenue and adjusted EBITDA grew 23% and 44% year over year, respectively, with both operating segments contributing double-digit growth.
- Management linked momentum to oncology limited-distribution drugs, infusion services, and home-health demand.
- Rating upgrades, lower-cost refinancing, and a reported 2.15x leverage ratio strengthened financial flexibility while acquisitions were integrated.
Management priorities
- Expand infusion services into 12–15 additional states over five years.
- Continue limited-distribution-drug launches, with 12 or more targeted this year, and expand the portfolio beyond 155 products.
- Invest in AI, automation, and Lean Sigma while integrating Amedisys and LHC assets and evaluating disciplined M&A.
Follow BTSGU with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Company context
Snapshot as of publicationBrightSpring Health Services, Inc. is a U.S.-based healthcare organization that provides a comprehensive suite of services directly to individuals in their homes and local communities. The company's primary focus is on delivering pharmacy and direct patient care services, encompassing both clinical treatment and supportive assistance. These services are specifically tailored for populations covered by Medicare, Medicaid, and private insurance. Care is administered by a network of clinical providers and pharmacists. Established in 1974, the firm is headquartered in Louisville, Kentucky, and adopted its current name, BrightSpring Health Services, Inc., in May 2021, having previously been known as Phoenix Parent Holdings Inc.
Historical context
All BTSGU earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
| RMD ResMed Inc. | FY2027 Q1 · Calendar Q4 2026 | +8.2% | -9.1% | ResMed reaffirms FY27 outlook as products and digital health support growth |
Latest beats and misses
Who reports nextBeat on EPS
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
- ABBVFY2026 Q3 · October 30, 2026+2.4% EPS+1.4% move
- GDFY2026 Q3 · October 30, 2026+9.0% EPS+0.5% move
- MGAFY2026 Q3 · October 30, 2026+15.8% EPS-1.4% move
Missed on EPS
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
- AMZNFY2026 Q3 · October 29, 2026-4.1% EPS-1.6% move
Get the BTSGU recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-04T19:07:31.258151+00:00
- FN2 earnings calendar · 2026-09-05T01:23:14.965082+00:00
- Polygon adjusted daily market bars · 2026-10-31T09:10:41.883904+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.